Humacyte, Inc. (NASDAQ:HUMA) Shares Sold by Victory Capital Management Inc.

Victory Capital Management Inc. lessened its stake in shares of Humacyte, Inc. (NASDAQ:HUMA) by 83.2% in the fourth quarter, Holdings Channel.com reports. The fund owned 12,911 shares of the company’s stock after selling 63,985 shares during the quarter. Victory Capital Management Inc.’s holdings in Humacyte were worth $65,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently modified their holdings of the company. Thrivent Financial for Lutherans purchased a new stake in shares of Humacyte in the third quarter valued at $712,000. Intech Investment Management LLC purchased a new stake in shares of Humacyte in the third quarter valued at $232,000. Charles Schwab Investment Management Inc. lifted its holdings in shares of Humacyte by 10.2% in the third quarter. Charles Schwab Investment Management Inc. now owns 721,318 shares of the company’s stock valued at $3,924,000 after purchasing an additional 66,946 shares in the last quarter. The Manufacturers Life Insurance Company lifted its holdings in shares of Humacyte by 30.5% in the third quarter. The Manufacturers Life Insurance Company now owns 45,575 shares of the company’s stock valued at $248,000 after purchasing an additional 10,656 shares in the last quarter. Finally, FMR LLC lifted its holdings in shares of Humacyte by 28.5% in the third quarter. FMR LLC now owns 94,387 shares of the company’s stock valued at $513,000 after purchasing an additional 20,930 shares in the last quarter. Institutional investors and hedge funds own 44.71% of the company’s stock.

Humacyte Trading Up 4.4 %

Shares of NASDAQ:HUMA opened at $3.32 on Monday. Humacyte, Inc. has a 1 year low of $2.75 and a 1 year high of $9.97. The business has a fifty day simple moving average of $3.81 and a 200 day simple moving average of $4.60. The firm has a market cap of $417.85 million, a price-to-earnings ratio of -2.48 and a beta of 1.36.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the company. HC Wainwright restated a “buy” rating and issued a $15.00 target price on shares of Humacyte in a report on Wednesday, March 12th. Benchmark restated a “buy” rating on shares of Humacyte in a report on Thursday, February 27th. Finally, D. Boral Capital reiterated a “buy” rating and set a $25.00 price objective on shares of Humacyte in a report on Friday, March 7th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Humacyte currently has a consensus rating of “Buy” and a consensus target price of $13.71.

Humacyte Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.